Nigeria state, TROVAN - Pfizer to settle out of court

Nigeria state, TROVAN - Pfizer to settle out of court

Joined: April 1st, 2004, 4:56 pm

April 15th, 2009, 7:12 am #1


http://uk.reuters.com/article/governmen ... 7820090403

 

Nigeria's Kano state, Pfizer reach broad agreement<span></span><span></span>

* Details remain to be worked out (Adds quote, background)
<span></span>
By Mike Oboh
<span></span>
KANO, Nigeria, April 3 (Reuters) - Nigeria's Kano state and drugmaker Pfizer Inc (<span>PFE.N</span>) have agreed to the broad terms of an out-of-court settlement in a multi-billion-dollar lawsuit over a 1996 drug trial, lawyers for both parties said on Friday.
<span></span>
The northern state of Kano sued the world's largest drugmaker in May 2007 for $2 billion in damages over the testing of the meningitis drug Trovan, which the authorities say killed 11 children and left dozens disabled.
<span></span>
"I want to report that broad and principal fundamental agreement has been reached between Kano state government and Pfizer," Pfizer's lead counsel in the case, Anthony Idigbe, told reporters after a court hearing.
<span></span>
The New York-based firm has denied all charges and says meningitis, not Trovan, killed the children or damaged their health. It said Trovan saved lives and was as effective as a more established drug used for comparison in the study.
<span></span>
Nigeria's federal government sued for an additional $6.5 billion in 2007 over the drug trial, though sources close to the negotiations have said it is expected to withdraw its case if Kano reaches a settlement.
<span></span>
Sources close to the negotiations told Reuters on Wednesday that the two sides were nearing a $75 million agreement, including the payment by Pfizer of $10 million legal fees, $30 million to Kano state and $35 million to victims and families. 
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

April 15th, 2009, 7:13 am #2

$10 million legal fees, $30 million to Kano state and $35 million to victims and families
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

April 15th, 2009, 7:17 am #3


still issues to be resolved, including how to "prevent any misappropriation of funds".

 

 

page 2

http://uk.reuters.com/article/governmen ... dChannel=0

 

The company, which has repeatedly said it hoped to reach an out-of-court agreement, said on Wednesday there was no final deal yet as there were still issues to be resolved, including how to "prevent any misappropriation of funds".
<span></span>
"We have agreed in broad principle for a settlement. We will work together on the details," Kano state Attorney General Aliyu Umar told reporters on Friday.
<span></span>
The civil and criminal cases launched by the Nigerian authorities have grown into a tangle of unresolved petitions and side issues, dragging from one adjournment to the next.
<span></span>
Court sources said a year ago that Pfizer had proposed to pay $10 million in compensation, rehabilitate the hospital where the Trovan study took place, and upgrade Kano's state-owned drug manufacturing company.
<span></span>
But Umar said at the time that the government wanted a better package for the victims.
<span></span>
Judge Shehu Atiku said the next hearing in the Kano case would be held on May 25 but said there was "a strong indication that the case is about to come to an end". (For full Reuters Africa coverage and to have your say on the top issues, visit: af.reuters.com/ ) (Writing by Nick Tattersall, editing by Will Waterman)
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

April 15th, 2009, 7:19 am #4

<table border="0" width="100%"><tr><td valign="top" colspan="2">Lilly ZYPREXA PAYOUT PROPAGANDA - Show us da money please!April 14 2009 at 9:01 AM</td><td align="right" valign="top"></td></tr><tr><td colspan="2">

Response to Lilly Zyprexa - class action group is seeking up to $6.8 billion in compensation
</td></tr><tr><td valign="bottom" colspan="3">
</td></tr><tr><td colspan="3">Lilly ZYPREXA PAYOUT PROPAGANDA
May 30, 2007, 11:31AM


http://tpmcafe.talkingpointsmemo.com/ta ... pagand.php

In 2004, the American Diabetes Association found that Zyprexa was more likely to cause diabetes than many other antipsychotic drugs.
A big hurdle with the Zyprexa issue is Lilly's credibility over their continuous PR on how they are going to pay out $1.2 billion . As long as they keep up this rhetoric and don't actually pay the issue won't go away.

They need to think about 'putting their money where their mouth is'.
Eli Lilly Zyprexa Hush Money
Zyprexa compensation fund now up to $1.2 billion,show us da money!

Consider this:
Latest media news PR "puff piece" sez that the Zyprexa compensation fund is up to $1.2 billion.Lilly's lawyers claim to have 'settled' the first wave (the so called 8,000) for $700 million.
Yesterday there are over 200 news wire Lilly press releases on how they are the good ole boys who will settle 18,000 MORE cases for $500 million ($27,000 per client)


DO THE MATH HERE- original 8,000 ~$700 million $87,000 per client half to lawyers?

Compare:today's news 18,000 for only $500 million equals $27,000 apiece ?

This sounds like bogus hush money rhetoric to appease Lilly critics? Their attached statement sez that these newer 18,000 cases are post 2003 black box warning and so have less merit/money.

Hello! I took zyprexa right out of the gate in 1996 I am possibly the #1 most viable and visible claimant and not only have I not been paid yet, I don't hear from them at all, something fishy here people.

<em><strong>Show us da money please!</strong></em>


Many of the longtime zyprexa users like myself who developed diabetes were given it 'off label' because it was being pushed on my doctor by Lilly drug reps.

The now notorious Zyprexa diabetes connection is elaborated at thousands of pages on line.
My own local clinic and clinics everywhere have stopped dispensing Zyprexa except as a PRN for acute cases.


Lilly made a mistake motivated by a desire for profits (greed) now it's time to face the music.Lilly occasionally comes out with theses periodic media PR's on compensation ($27,000 per person?) then nothing further happens and you wonder why victims get indignant.
Eli Lilly's $4.2 billion a year zyprexa gravy train will stall soon enough.

I am Daniel Haszard 4 year zyprexa user who got diabetes from i
 
</td></tr></table>
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

April 15th, 2009, 7:26 am #5

http://uk.reuters.com/article/governmen ... 7820090403

 

Nigeria's Kano state, Pfizer reach broad agreement<span></span><span></span>

* Details remain to be worked out (Adds quote, background)
<span></span>
By Mike Oboh
<span></span>
KANO, Nigeria, April 3 (Reuters) - Nigeria's Kano state and drugmaker Pfizer Inc (<span>PFE.N</span>) have agreed to the broad terms of an out-of-court settlement in a multi-billion-dollar lawsuit over a 1996 drug trial, lawyers for both parties said on Friday.
<span></span>
The northern state of Kano sued the world's largest drugmaker in May 2007 for $2 billion in damages over the testing of the meningitis drug Trovan, which the authorities say killed 11 children and left dozens disabled.
<span></span>
"I want to report that broad and principal fundamental agreement has been reached between Kano state government and Pfizer," Pfizer's lead counsel in the case, Anthony Idigbe, told reporters after a court hearing.
<span></span>
The New York-based firm has denied all charges and says meningitis, not Trovan, killed the children or damaged their health. It said Trovan saved lives and was as effective as a more established drug used for comparison in the study.
<span></span>
Nigeria's federal government sued for an additional $6.5 billion in 2007 over the drug trial, though sources close to the negotiations have said it is expected to withdraw its case if Kano reaches a settlement.
<span></span>
Sources close to the negotiations told Reuters on Wednesday that the two sides were nearing a $75 million agreement, including the payment by Pfizer of $10 million legal fees, $30 million to Kano state and $35 million to victims and families. 
Pfizer awarded for human rights in research
 

http://www.outsourcing-pharma.com/Clini ... n-research
By Phil Taylor, 07-Apr-2009
Related topics: Clinical evolution, Clinical Development, Phase I-II
<h4></h4>


Pfizer has become the first drugmaker to win accreditation for protecting the human rights of subjects enrolled into early-stage clinical trials under a scheme operated by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).





The AAHRPP accreditation was awarded to Pfizer's clinical research units in New Haven, Connecticut in the US, Brussels in Belgium and Singapore. The company conducts most of its Phase I clinical research at these three centres.







To gain accreditation, organisations have to show tangible evidence of a commitment to scientifically and ethically sound research based on policies, procedures and practices, according to the AAHRPP.







The independent, non-profit accrediting body was established in April 2001 and started receiving applications in 2002. The path to winning accreditation involves carrying out a self-assessment and submission of an application, followed by an onsite evaluation and review by the AAHRPP Council. Once awarded, accreditation is valid for three years.







Fees range from $6,400 to around $80,000 based on the number of active clinical trial protocols, according to the AAHRPPs website.







To earn its accreditation, Pfizer underwent a 15-month examination of the clinical research practices at its Phase I units and submitted an application of more than 1,000 pages to AAHRPP.







The company said it sought accreditation because it wanted to show commitment to integrity in research and .. be among more than 150 of the world's best universities, hospitals, institutional review boards (IRBs) contract research organizations (CROs), and other organizations that are AAHRPP-accredited.







Pfizer has implemented a number of other initiatives recently to shore up its clinical research policies, and in November 2008 adopted a requirement that it would only use institutional review bodies (IRBs) for its US trials that are themselves AAHRPP-accredited.
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

April 15th, 2009, 7:29 am #6

Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

April 15th, 2009, 7:35 am #7


<a rel="nofollow">Pfizer Is First Pharmaceutical Company to Earn Accreditation</a>

 

http://www.aahrpp.org/www.aspx?PageID=287



<strong>FOR IMMEDIATE RELEASE:</strong> 12:00 P.M., Noon (EDT), Thursday, April 2, 2009

<strong>CONTACT: </strong>David Ward, (202) 783-1112 [url=mailto:dward@aahrpp.org]dward@aahrpp.org[/url]

<strong>Accreditation Gains Major Foothold in Industry Sponsored Research</strong>

<strong>Washington, D.C.,</strong> April 1, 2009Accreditation of human research protection programs is expanding into clinical trials conducted by Pfizer Inc., and to three more of the nations social science and behavioral research universities, the Association for the Accreditation of Human Research Protection Programs, Inc., announced today.

AAHRPP has accredited another 16 organizations, expanding coverage to a total of 175 organizations representing more than 830 entities that have met its standards for accreditation since 2003. Pfizer, the worlds largest research-based pharmaceutical company, is the first in its industry to gain accreditation for its phase 1 clinical research units.

The accreditation of Utah State University, Binghamton University, State University of New York, and the University of California, Riverside, as well as Pfizer, attests to the importance of protecting research participants at all universities and in industry, as well, said the AAHRPPs President and CEO Marjorie A. Speers, Ph.D., in announcing the new accreditations.

<strong>More people protected by the highest standards</strong>

Binghamton University has built a reputation as an outstanding institution with state-of-the-art research activities and facilities carried out by excellent faculty, students and staff.  AAHRPP accreditation assures our excellence in human research studies, said Gerald Sonnenfeld, Vice President for Research.

Charles Louis, Vice Chancellor for Research at the University of California, Riverside, said, AAHRPP accreditation demonstrates to participants, researchers, funders, and other partners our commitment to ensuring the highest ethical standards in the conduct of research at UC Riverside.

Pfizer is proud to be the first pharmaceutical or biotech company to obtain AAHRPP accreditation and take our place alongside some of the best universities and hospitals that are also AAHRPP-accredited. said Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer. Accreditation is part of Pfizers ongoing efforts to demonstrate our commitment to integrity and increased transparency in research and operations, a program initiated by Kindler when he became Pfizers Chairman and CEO two years ago.

<strong>Pfizer expands effort to earn public trust</strong>

In addition to earning accreditation for its Clinical Research Units, located in New Haven, CT, Brussels, Belgium, and Singapore,  the company will use only central institutional review boards (IRBs) accredited by AAHRPP to approve its U.S. multi-site clinical trials.

Justin McCarthy, Chief Counsel for Pfizer Global Research and Development, said Pfizer will also encourage its study teams to use research sites accredited by AAHRPP, and will continue to support the adoption of the AAHRPP standards internationally.

Pfizers commitment to accreditation will expand the number of participants covered by AAHRPP standards, Speers said, And thats important, because setting uniform, high standards across the research enterprise¯in industry, government, and non-profit sectorswill improve protections for research participants in the U.S. and internationally.

The newly accredited organizations are:

<strong>Full Accreditation</strong>
  • <strong>Binghamton University, State University of New York,</strong> Binghamton, NY</li>
  • <strong>Birmingham VA Medical Center,</strong> Birmingham, AL</li>
  • <strong>Duke Medicine,</strong> Durham, NC</li>
  • <strong>James H. Quillen VA Medical Center,</strong> Mountain Home, TN</li>
  • <strong>Lehigh Valley Health Network,</strong> Allentown, PA</li>
  • <strong>Rhode Island Hospital, Hasbro Childrens Hospital, The Miriam Hospital, Emma Pendleton Bradley Hospital and Newport Hospital as part of Lifespan,</strong> Providence, RI</li>
  • <strong>Minneapolis Veterans Affairs Medical Center,</strong> Minneapolis, MN</li>
  • <strong>Nemours,</strong> Jacksonville, FL</li>
  • <strong>Pfizer Clinical Research Units,</strong> New Haven, CT, Brussels, Belgium, and Singapore</li>
  • <strong>RCRC Independent Review Board,</strong> LLC, Austin, TX</li>
  • <strong>San Francisco Veterans Affairs Medical Center,</strong> San Francisco, CA</li>
  • <strong>St. Cloud Veterans Affairs Medical Center,</strong> St. Cloud, MN</li>
  • <strong>University of California, Riverside,</strong> Riverside, CA</li>
  • <strong>Utah State University,</strong> Logan, UT</li>
<strong>Qualified Accreditation</strong>
  • <strong>Kansas City Veterans Administration Medical Center,</strong> Kansas City, MO</li>
  • <strong>White River Junction, VT, Veterans Affairs Medical Center,</strong> White River Junction, VT</li>
AAHRPP is a non-profit organization that works with organizations that conduct human research to raise the level of protection for research participants. AAHRPP accredits organizations that can demonstrate they provide participant safeguards that surpass the threshold of state and federal requirements. The accreditation program utilizes a voluntary, peer-driven educational model. For organizations interested in learning more about accreditation, visit http://www.aahrpp.org/.

Through the rigorous accreditation process, organizations must demonstrate that they have built extensive safeguards into every level of their research operation and that they adhere to the highest standards for research. AAHRPPs standards exceed federal regulations by requiring organizations to address conflict of interest, to provide community outreach and education and to apply the same stringent protections to all research involving human participants. (Under federal regulations, such protections are mandated only for federally sponsored or regulated research.) The accreditation process typically results in system-wide improvements that enhance protections for research participants and promote high-quality research.

Accreditation is available to U.S. and international organizations that conduct biomedical, behavioral or social sciences research involving human participants. Decisions on accreditation are announced quarterly, and accreditation is valid for three years
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

April 15th, 2009, 7:39 am #8

http://uk.reuters.com/article/governmen ... 7820090403

 

Nigeria's Kano state, Pfizer reach broad agreement<span></span><span></span>

* Details remain to be worked out (Adds quote, background)
<span></span>
By Mike Oboh
<span></span>
KANO, Nigeria, April 3 (Reuters) - Nigeria's Kano state and drugmaker Pfizer Inc (<span>PFE.N</span>) have agreed to the broad terms of an out-of-court settlement in a multi-billion-dollar lawsuit over a 1996 drug trial, lawyers for both parties said on Friday.
<span></span>
The northern state of Kano sued the world's largest drugmaker in May 2007 for $2 billion in damages over the testing of the meningitis drug Trovan, which the authorities say killed 11 children and left dozens disabled.
<span></span>
"I want to report that broad and principal fundamental agreement has been reached between Kano state government and Pfizer," Pfizer's lead counsel in the case, Anthony Idigbe, told reporters after a court hearing.
<span></span>
The New York-based firm has denied all charges and says meningitis, not Trovan, killed the children or damaged their health. It said Trovan saved lives and was as effective as a more established drug used for comparison in the study.
<span></span>
Nigeria's federal government sued for an additional $6.5 billion in 2007 over the drug trial, though sources close to the negotiations have said it is expected to withdraw its case if Kano reaches a settlement.
<span></span>
Sources close to the negotiations told Reuters on Wednesday that the two sides were nearing a $75 million agreement, including the payment by Pfizer of $10 million legal fees, $30 million to Kano state and $35 million to victims and families. 
</a><a href="mailto:?body=An%20important%20link%20from%20the%20AAHRPP(R)%20Web%20site%20for%20you:" rel="nofollow">http://www.aahrpp.org/www.aspx?PageID=221">

 

http://www.aahrpp.org/www.aspx?PageID=221

<a rel="nofollow">How to Conduct a Self-Assessment</a>

<strong><em>At the heart of the accreditation process is a comprehensive self-assessment </em></strong>during which an Organization reviews its Human Research Protection Program and evaluates its compliance with 20 AAHRPP standards and 77 elements. Given the scope of these standards and elements, it is not surprising that one of the most frequent questions that AAHRPP receives is Where do we begin?

Following are some tips designed to answer that question. As you move forward with accreditation, keep in mind that the process is meant to be rigorous, not overwhelming.

In general

  • <strong>Read, read, and read some more.</strong> Start with the AAHRPP Web site and newsletter, AAHRPP Advance. Read institutional review board (IRB) journals, and check the Web sites of other accredited organizations and relevant federal agencies or offices, such as the Food and Drug Administration and the Office for Human Research Protections. On the AAHRPP Web site, under Apply, pay particular attention to the sections on How to apply and this section - How to conduct a self-assessment. Information on the AAHRPP Web site is available to all at no charge. Work at your own pace. You can start the self-assessment whenever you are ready and work on it as long as necessary.</li>
  • <strong>Get commitment from the highest level.</strong> Accreditation is attainable only if your entire Organization fosters a culture of accountability and makes human research protection a priority. When you begin the process, obtain organizational commitment, backed by budgetary support.</li>
  • <strong>Establish an accreditation team.</strong> Identify key individuals who can help with accreditation, and invite them to join the team. Be clear about the responsibilities of each team member, and set realistic deadlines for meeting those responsibilities. To oversee the accreditation process, choose a team leader who is organized and has an organizational perspective with an understanding of how all the components of your Human Research Protection Program fit together.</li>
  • <strong>Strive for protection, not perfection.</strong> The goal is to have an effective Human Research Protection Program, whose activities achieve the desired outcome: to protect research participants. If practices and policies meet the AAHRPP Element and Standard, do not spend time revising them further. Instead, focus your energy on identifying and correcting gaps.</li>
  • <strong>Check for inconsistencies.</strong> Do your procedures match your forms and checklists? Are your procedures an accurate reflection of how your organization oversees its research activities and protects research participants?</li>
  • <strong>Create and maintain an accreditation intranet site.</strong> If you have the resources, this is a convenient way to keep everyone in your organization up to date on issues, news, schedules, and other accreditation-related information.</li>
<strong>Getting ready</strong>
  • <strong>Download the </strong>Evaluation Instrument for Accreditation. Read through the entire document before tackling any of the steps in earnest. Familiarize yourself with the standards and elements.</li>
  • <strong>Gather all written policies and procedures, and organize them by topic</strong>. Remember to think in terms of the entire Human Research Protection Program, and, if applicable, include policies and procedures for areas such as human resources, budgeting, counseling services, pharmacy, student orientation, corporate ethics, and corporate compliance. In most cases, your Human Research Protection Program will have a policy, procedure, or practice to demonstrate that you meet the element and the standard.</li>
  • <strong>Share the load.</strong> As you read over the self-assessment, identify experts for each Domain and even for each Standard within a Domain. Then, enlist their help.</li>
<strong>Specific tips</strong>
  • <strong>Save the first Element, I.1.A, for last.</strong> This Element is global in nature and cannot adequately be addressed until you have completed the entire self-assessment.</li>
  • <strong>Start with Domain II: Research Review Unit, including the IRB</strong>. This Domain will be most familiar to you and, therefore, easiest to complete.</li>
  • <strong>Tackle the Evaluation Instrument Element by Element. </strong>For each Element, identify the policies and procedures that spell out how your Human Research Protection Program meets the Element. If someone in your Organization is an expert in the requirements covered by a particular Element, assign the Element to that expert. If an Element does not apply to your Organization, just indicate that it is not applicable.</li>
  • <strong>Dont write. Instead, list.</strong> Most Elements can be addressed by your existing documents. Examples include policy statements, procedures, checklists, guidelines, educational materials, job descriptions, bylaws, memoranda, forms, templates, strategic plans, slide presentations, Web sites, charters, and mission statements. Find the appropriate document, and cite the name and relevant section.</li>
  • <strong>If you must write, do it for your organization not for AAHRPP</strong>. If you find yourself writing a detailed explanation in response to an element, chances are you need to create a document for your own Organization. Once you have done that, reference the document for the applicable Element.</li>
  • <strong>Some Elements do not require documentation.</strong> These Elements are evaluated during the site visit, through interviews with members of your organization. For these Elements, provide a brief description of your practice.</li>
  • <strong>Identify and fill in the gaps.</strong> Most self-assessments identify a number of gaps between the AAHRPP standards and your Organizations human research protection practices. When you find a gap, design a policy, procedure, or practice that makes sense for your Human Research Protection Program and then use the AAHRPP Standards to refine what you have developed. Communicate the new policy, procedure, or practice throughout your Human Research Protection Program.</li>
  • <strong>Construct an Element-by-Element index of your supporting documents.</strong> For each Element, list the supporting document, assign it a number, and provide a very brief explanation. Use page numbers, paragraph numbers, item numbers, titles, and headings to pinpoint the information. (This index becomes Section C of your accreditation application.)</li>
  • <strong>Copy your documents.</strong> Provide one copy of each document cited in your element-by-element index. Do not include non-organizational documents. Cross-reference and cite each document as many times as necessary, but include only one copy. (These copies become Section D of your accreditation application.)</li>
  • <strong>Dont be afraid to ask.</strong> AAHRPP is available as a resource throughout the accreditation process. If you have questions or need help, just ask.</li>
Once you start the self-assessment, you will be surprised at how quickly everything falls into place and how valuable the self-assessment proves in strengthening your Human Research Protection Program
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

April 15th, 2009, 7:45 am #9


<a rel="nofollow">Board of Directors</a>

 

http://www.aahrpp.org/www.aspx?PageID=150$9$100



AAHRPP's Board of Directors is responsible for overseeing the accreditation process. The Board is composed of individuals concerned with research involving humans as research participants. Five of AAHRPP's directors represent research participants or other community stakeholders.
<table style="width:90%;border-collapse:collapse;" border="0" cellspacing="0"><tr><td><span>Barbara E. Bierer, M.D.</span>
<span>Senior Vice President for Research
Brigham and Women's Hospital
Professor of Medicine (Pediatrics)
Harvard Medical School </span>

</td></tr><tr><td><span>Thomas F. Boat, M.D., Chair</span>
<span>Professor of Pediatrics
Cincinnati Children's Hospital Medical Center
Personalized and Predictive Medicine</span>

</td></tr><tr><td><span>Diana T. Chingos, M.A., M.S.</span>
<span>Patient Advocate
University of Southern California</span>

</td></tr><tr><td><span>Cathryn M. Clary, M.D., M.B.A.</span>
<span>Vice President, U.S. External Medical Affairs, Medical Division
Pfizer Inc</span>

</td></tr><tr><td><span>Elizabeth H. Cothran, M.S., C.I.P., Secretary</span>
<span>Director, Office of Research Subject Protection
Baylor Research Institute</span>

</td></tr><tr><td><span>Sandra Harris-Hooker, Ph.D.</span>
<span>Vice President and Associate Dean for Sponsored Research Administration
Morehouse School of Medicine</span>

</td></tr><tr><td><span>Christopher C. Houston, Esquire</span>
<span>Director of Real Estate Development and General Counsel
Redevelopment Authority of the County of Cumberland</span>

</td></tr><tr><td><span>Bernard Lo, M.D.</span>
<span>Professor of Medicine
Director, Program in Medical Ethics
University of California, San Francisco </span>

</td></tr><tr><td><span>James P. McNulty, A.B.</span>
<span>Vice President of Peer Services
The Depression and Bipolar Support Alliance </span>

</td></tr><tr><td><span>Brent Miller, Ph.D., Vice-Chair</span>
<span>Vice President for Research
Professor of Family and Human Development
Utah State University</span>

</td></tr><tr><td><span>Suzanne R. Pattee, J.D.</span>
<span>Vice President of Regulatory and Patient Affairs
Cystic Fibrosis Foundation</span>

</td></tr><tr><td><span>Robert A. Sandhaus, Ph.D., M.D.</span>
<span>Professor of Medicine
National Jewish Medical and Research Center</span>

</td></tr><tr><td><span>Steven R. Smith, J.D.</span>
<span>Professor of Law
President and Dean
California Western School of Law</span>

</td></tr><tr><td><span>Stephanie S. Spangler, M.D.</span>
<span>Deputy Provost, Biomedical and Health Affairs
Yale University</span>

</td></tr><tr><td><span>Douglas L. Strong, M.B.A., Treasurer</span>
<span>Director and CEO
University of Michigan Hospitals and Health System</span>

</td></tr><tr><td><span>James A. Weyhenmeyer, Ph.D.</span>
<span>SUNY Senior Vice Provost for Research & SUNY Research Foundation Senior Vice President
The Research Foundation of State University of New York</span>

</td></tr></table><a rel="nofollow"></a>
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

April 15th, 2009, 7:47 am #10

<table style="width:90%;border-collapse:collapse;" border="0" cellspacing="0"><tr><td>
<span>Cathryn M. Clary, M.D., M.B.A.</span>
<span>Vice President, U.S. External Medical Affairs, Medical Division
Pfizer Inc</span>


http://www.aahrpp.org/www.aspx?PageID=150$9$100

AAHRPP's Board of Directors is responsible for overseeing the accreditation process. The Board is composed of individuals concerned with research involving humans as research participants. Five of AAHRPP's directors represent research participants or other community stakeholders

</td></tr><tr><td><span></span></td></tr></table>
Quote
Like
Share